Comparative Pharmacology
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus TOLECTIN DS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHILDREN S IBUPROFEN versus TOLECTIN DS.
CHILDREN'S IBUPROFEN vs TOLECTIN DS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Non-selective cyclooxygenase (COX-1 and COX-2) inhibitor, reducing prostaglandin synthesis, which mediates inflammation, pain, and fever.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2) enzymes, reducing prostaglandin synthesis.
Oral: 200-400 mg every 6-8 hours as needed; maximum daily dose: 1200 mg (OTC) or 3200 mg (prescription).
400 mg orally three times daily; maximum dose 1800 mg/day.
None Documented
None Documented
2-4 hours (terminal elimination half-life in children; may be prolonged in neonates or hepatic impairment)
Terminal elimination half-life approximately 1 hour; clinical context: requires frequent dosing every 6-8 hours due to short half-life.
Renal: 90% (primarily as conjugated metabolites, <10% unchanged); biliary/fecal: minor
Primarily renal, 95% of a dose excreted in urine as glucuronide conjugates and oxidative metabolites; less than 5% fecal.
Category D/X
Category C
NSAID
NSAID